Prostate Cancer

AMG 160 showed preliminary evidence of efficacy with a manageable safety profile as treatment of patients with metastatic castration-resistant prostate cancer who have been heavily pretreated.

A primary analysis from the phase 3 IPATential150 trial demonstrated the benefit of the addition of ipatasertib to abiraterone acetate and prednisone in the treatment of patients with metastatic castration-resistant prostate cancer with PTEN loss, according to results presented at the 2020 ESMO Virtual Congress.

Updated findings from the randomized, open-label phase 3 PROfound trial indicate that olaparib induces a significantly longer duration of overall survival versus enzalutamide or abiraterone plus prednisone in metastatic castration-resistant prostate cancer tumors with at least 1 alteration in BRCA1, BRCA2, or ATM and disease that has progressed during previous treatment with a next-generation hormonal agent.

PARP inhibitors have propelled the field of metastatic castration-resistant prostate cancer forward as the next class of therapeutics to advance outcomes.

A Fast Track designation has been granted by the FDA to EPI-7386, a selective androgen receptor inhibitor, which is a potential treatment for adult patients with metastatic castration-resistant prostate cancer that is resistant to standard-of-care therapy.

A higher percentage of patients with nonmetastatic castration-resistant prostate cancer were alive at 3 years on treatment with darolutamide compare with placebo, according to published results from the final analysis of the phase 3 ARAMIS clinical trial.

Michael J. Morris, MD, discusses the safety and clinical activity of atezolizumab plus radium-223 dichloride in patients with second-line metastatic castration-resistant prostate cancer.

In an interview with Targeted Oncology, Andrei Gafita, MD, discussed the recent findings from the international multicenter retrospective analysis of LuPSMA as treatment of patients with metastatic castration-resistant prostate cancer, and how these findings and more clinical trials could lead to the approval of this treatment for patients who have exhausted all other standard treatments.

During a virtual Case Base Peer Perspectives event, Eleni Efstathiou, MD, PhD, a discussed treatment options for a 57-year-old African American man with nonmetastaic castration resistant prostate cancer.

During a virtual Case Based Peer Perspectives event, David I. Quinn, MD, MBBS, PhD, reviewed the case of a 60-year old male patient with metastatic castration-resistant prostate cancer.

During a virtual Case Based Peer Perspectives event, Nicholas J. Vogelzang, MD, reviewed the case of a 75-year-old man diagnosed with metastatic castration-resistant prostate cancer.

Short and longterm safety and a meaningful reduction in worst pain were reported in patients with metastatic castration-resistant prostate cancer, based on results from the REASSURE trial.

The FDA placed a partial clinical hold on enrollment to the phase 1 P-PSMA-101-001 trial evaluating P-PSMA-01 as treatment of patients with metastatic castration-resistant prostate cancer.

Much of the most important work that must be done during the development of a new cancer medication is often accomplished long after FDA approval, wrote Arjun V. Balar, MD.

Andrei Gafita, MD, discusses the overall survival in patients with metastatic castration-resistant prostate cancer who received 177Lutetium-prostate-specific membrane antigen radionuclide treatment.

Prostate-specific antigen changes were observed 6 weeks after the administration of 177Lu-PSMA in men with metastatic castration-resistant prostate cancer, suggesting a prognostic value for long-term clinical benefit, according to a single center retrospective analysis.

There was no difference in the occurrence of late toxicities between patients treated with radiotherapy alone or radiotherapy with short-term androgen deprivation therapy.

In an interview with Targeted Oncology, A. Oliver Sartor, MD, discussed the findings for subsequent 177Lu-PSMA following Radium-223 as treatment of patients with metastatic castration-resistant prostate cancer, as well as the next steps for this research.

The national RESPOND study is looking to determine potential underlying factors for the increased burden among African American males compared with American men of European descent and has identified novel variations among the African American population; however, an analysis from the study concluded that genomic alterations in known therapeutic targets show similar frequencies between the 2 racial groups.

Hagen F. Kennecke, MD, MHA, FRCP, medical oncologist, medical director of the Virginia Mason Cancer Institute and current chair of the NCI Rectal-Anal Cancer Task Force, discusses the treatment and screening decision making process for patients with prostate cancer.

"Men with advanced prostate cancer have exhausted local therapies and are now moving on to systemic options."

In an interview with Targeted Oncology, Neal Shore, MD, director, Carolina Urologic Research Center, discussed the OS analysis for the phase 3 ARAMIS study and explained a match-adjusted indirect comparison. He also discussed how these data connect with presentations around the 3 approved agents for nmCRPC being presented at AUA 2020.

Oral relugolix received a priority review designation from the FDA for the treatment of patients with advanced prostate cancer.

“The early results of the IPATential150 study are encouraging in our ongoing mission to develop new treatment options for people with advanced prostate cancer.”

"Cancer is now the number 1 cause of death in many parts of the United States and overall, men are at a 50% likelihood of having some sort of cancer diagnosed in their lifetime, where it is slightly lower in women at about a third."